secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABVC BIOPHARMA, INC. (ABVC)
CIK:        0001173313
Form:       8-K/A
Filed at:   2024-01-26T23:59:59+00:00
Accession:  0001213900-24-006637
Event type: m_and_a
Sentiment:  negative
Materiality: 0.60
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ABVC BioPharma files AIBL audited financials: zero revenue, $598K deficit, going concern
--------------------------------------------------------------------------------

- AIBL had no revenue, $597,886 accumulated deficit, and zero cash as of Sep 30, 2023.
- Pro forma combined net loss for nine months ended Sep 30, 2023 was $8.18M, vs ABVC standalone $7.58M.
- ABVC and BioLite each received 23M AIBL shares at $10/share, giving ABVC controlling interest.
- Licensed products for MDD/ADHD valued at $667M by third party; potential milestones of $3.5M plus 5% royalties.
- Auditor expresses substantial doubt about AIBL's ability to continue as a going concern.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1173313/000121390024006637/0001213900-24-006637-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1173313/000121390024006637/ea192147-8ka1_abvcbio.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-006637

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer